
The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.
Luis E. Raez, MD, FACP, FASCO, dives into evolving practices in molecular testing for patients with lung cancer.
Luis E. Raez, MD, FACP, FASCO, dives into the evolving use of molecular testing for patients with lung cancer. Raez is the medical director of Memorial Cancer Institute, oncology research director of Memorial Health Care System, and director of the Thoracic Oncology Program at the Florida Society of Clinical Oncology. He is also a clinical associate professor of medicine at Florida International University and a visiting professor of medicine at Cayetano Heredia University in Peru.






